Debra Stephanie Barker
Chief Tech/Sci/R&D Officer at DESTINY PHARMA PLC
Net worth: 36 120 $ as of 2024-04-29
Debra Stephanie Barker active positions
Companies | Position | Start | End |
---|---|---|---|
BERGENBIO ASA | Director/Board Member | 2019-03-12 | - |
DESTINY PHARMA PLC | Director/Board Member | 2019-12-31 | - |
Chief Tech/Sci/R&D Officer | 2023-09-30 | - | |
Independent Dir/Board Member | 2019-12-31 | - | |
Chief Executive Officer | 2023-05-24 | 2023-08-31 | |
CUREVAC N.V. | Director/Board Member | 2022-06-21 | - |
ARIX BIOSCIENCE PLC | Director/Board Member | 2022-08-09 | - |
Independent Dir/Board Member | 2022-08-09 | - | |
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Director/Board Member | - | - |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Director/Board Member | - | - |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Director/Board Member | 2022-07-31 | - |
Career history of Debra Stephanie Barker
Former positions of Debra Stephanie Barker
Companies | Position | Start | End |
---|---|---|---|
SPEXIS AG | Chief Tech/Sci/R&D Officer | 2017-04-30 | 2018-12-30 |
NOVARTIS AG | Corporate Officer/Principal | - | - |
Training of Debra Stephanie Barker
Queens' College Cambridge | Doctorate Degree |
King's College London | Graduate Degree |
Statistics
International
United Kingdom | 6 |
Switzerland | 4 |
Germany | 3 |
Operational
Director/Board Member | 7 |
Chief Tech/Sci/R&D Officer | 2 |
Independent Dir/Board Member | 2 |
Sectoral
Health Technology | 8 |
Consumer Services | 3 |
Finance | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 6 |
---|---|
SPEXIS AG | Health Technology |
NOVARTIS AG | Health Technology |
BERGENBIO ASA | Health Technology |
DESTINY PHARMA PLC | Health Technology |
CUREVAC N.V. | Health Technology |
ARIX BIOSCIENCE PLC | Finance |
Private companies | 3 |
---|---|
Hutman Diagnostics AG
Hutman Diagnostics AG Medical SpecialtiesHealth Technology Hutman Diagnostics AG is a Swiss company that specializes in the development and management of in vitro diagnostics products. | Health Technology |
CureVac SE
CureVac SE BiotechnologyHealth Technology CureVac SE engages in the development of tumor immunotherapy. Its pipeline include mRNA-based Cancer Immunotherapies; Protein-based therapies; and mRNA-based Prophylactic Vaccines. The company was founded by Ingmar Hoerr, Florian von der Mülbe, Hans Georg Rammensee, Günther Jung, and Steve Pascolo in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
Arix Bioscience /Venture Capital/
Arix Bioscience /Venture Capital/ Investment ManagersFinance Arix Bioscience /Venture Capital/ (Arix Bioscience) is a venture capital subsidiary of Arix Bioscience Plc founded in 2015 by Christopher Thomas Evans, Jonathan M. Peacock and Joseph Anderson. The firm is headquartered in London, United Kingdom with an additional offices in New York. | Finance |